Hess, G http://orcid.org/0000-0002-9282-5688
Keller, U
Scholz, C W
Witzens-Harig, M
Atta, J
Buske, C
Kirschey, S
Ruckes, C
Medler, C
van Oordt, C
Klapper, W
Theobald, M
Dreyling, M
Article History
Received: 26 November 2014
Revised: 20 January 2015
Accepted: 30 January 2015
First Online: 13 March 2015
Competing interests
: Johannes Atta received honoraria from Pfizer and Roche. Christian Buske received honoraria and research funding from Roche and Janssen and honoraria from Pfizer and Pharmacyclics. Martin Dreyling received research funding and speaker’s honoraria from Pfizer, Mundipharma and Roche. Georg Hess received research funding and honoraria from and is on the advisory committee of Pfizer, research funding from Mundipharma and honoraria from and is on the advisory committee of Roche. Ulrich Keller received honoraria from and is on the advisory committee of Pfizer and speaker and advisory board honoraria from Mundipharma and Roche. Christian Scholz received honoraria from and is on the advisory committee of Pfizer, research funding and honoraria from and is on the advisory committee of Mundipharma and honoraria from and is on the advisory committee of Roche. Mathias Witzens-Harig received research funding and honoraria from and is on the advirsory committee of Pfizer and Roche and honoraria from Mundipharma. The other authors declare no conflict of interest.